NCT05612958 is a NA clinical trial of DKM-410 in Nasolabial Folds, sponsored by Dongkook Pharmaceutical Co., Ltd..

Who is sponsoring NCT05612958?

NCT05612958 is sponsored by Dongkook Pharmaceutical Co., Ltd..

What drugs are being tested in NCT05612958?

Interventions in NCT05612958: DKM-410, Juvederm ULTRA PLUS XC 1.0ml.

What condition does NCT05612958 study?

NCT05612958 studies Nasolabial Folds.

Is NCT05612958 still recruiting?

NCT05612958 is currently completed. Last updated 14 November 2022.

Last reviewed 2022-11-14 · How we verify

NCT05612958

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of a 'Graft/Prosthesis, Biomaterial (DKM410)' in the Treatment of Both Nasolabial Folds

Completed NA Last updated 14 November 2022

What this trial tests

NA trial testing DKM-410 in Nasolabial Folds in 82 participants. Completed in 28 June 2022.

Timeline

23 March 2021

Primary endpoint
14 January 2022

28 June 2022

Quick facts

Lead sponsor	Dongkook Pharmaceutical Co., Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	82
Start date	23 March 2021
Primary completion	14 January 2022
Estimated completion	28 June 2022
Sites	1 location across South Korea

Drugs / interventions tested

DKM-410
Juvederm ULTRA PLUS XC 1.0ml

Conditions studied

Nasolabial Folds — all drugs for Nasolabial Folds →

Sponsor

Dongkook Pharmaceutical Co., Ltd. — full company profile →

Who can join

19 and older, any sex, with Nasolabial Folds. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to assess the efficacy and safety of a 'Graft/prosthesis, biomaterial (DKM410)' in the treatment of both nasolabial folds.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Dongkook Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT06490328 — Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer · Phase 3 · recruiting
NCT04947631 — Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia · Phase 3 · completed
NCT06021444 — Efficacy and Safety of DKM420 in Patients With Osteoarthritis of Knee · NA · completed
NCT06021418 — Efficacy and Safety of DKB-119 in Patients in Crow's Feet · NA · unknown
NCT05749380 — Pharmacokinetics and Safety of AmBisome and DKF-5122 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05612958 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dongkook Pharmaceutical Co., Ltd.
Last refreshed: 14 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05612958.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing